Literature DB >> 1384679

Translocations involving 12p in acute myeloid leukemia: association with prior myelodysplasia and exposure to mutagenic agents. United Kingdom Cancer Cytogenetics Group (UKCCG).

.   

Abstract

Six cases of acute myeloid leukemia (AML) with translocations involving 12p are described. The patients were one child age 7 yrs and five adults with an age range of 20-66 yrs (median 46 yrs). In two patients AML followed treatment for acute lymphoblastic leukemia (ALL), in one case after 11 years disease-free survival. Of the remaining four patients, two had been occupationally exposed to possible mutagens and three had a previous myelodysplastic phase. Two patients achieved complete remission; survival for the six cases was between 1 and 24 months (median 6.5 months). The breakpoints in 12p occurred in p11, p12, and p13, indicating that several sites are important in these rearrangements, and it is suggested that t(12;17)(p11;q11) is a new nonrandom abnormality in AML.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384679     DOI: 10.1002/gcc.2870050313

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  3 in total

1.  New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.

Authors:  Alison Walker; Krzysztof Mrózek; Jessica Kohlschmidt; Kathleen W Rao; Mark J Pettenati; Lisa J Sterling; Guido Marcucci; Andrew J Carroll; Clara D Bloomfield
Journal:  Genes Chromosomes Cancer       Date:  2012-12-10       Impact factor: 5.006

2.  Acute myeloid leukemia with t(4;12)(q12;p13): report of 2 cases.

Authors:  Kyung-Hee Kim; Moon Jin Kim; Jeong-Yeal Ahn; Pil-Whan Park; Yiel-Hea Seo; Ji-Hun Jeong
Journal:  Blood Res       Date:  2016-06-23

3.  ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer.

Authors:  Franklin C Harwood; Ramon I Klein Geltink; Brendan P O'Hara; Monica Cardone; Laura Janke; David Finkelstein; Igor Entin; Leena Paul; Peter J Houghton; Gerard C Grosveld
Journal:  Sci Adv       Date:  2018-09-12       Impact factor: 14.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.